Jiangsu Hengrui Pharmaceuticals Co (MEX:1276N) Cyclically Adjusted PB Ratio: (As of Aug. 10, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:1276N Jiangsu Hengrui Pharmaceuticals Co Ltd MEX:1276N
60 GF Score
Price MXN125.92
GF Value MXN142.94
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Jiangsu Hengrui Pharmaceuticals Co Cyclically Adjusted PB Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PB Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Jiangsu Hengrui Pharmaceuticals Co  (MEX:1276N) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Jiangsu Hengrui Pharmaceuticals Co Cyclically Adjusted PB Ratio Related Terms


Jiangsu Hengrui Pharmaceuticals Co Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Jiangsu Hengrui Pharmaceuticals Co's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jiangsu Hengrui Pharmaceuticals Co Cyclically Adjusted PB Ratio Chart

Jiangsu Hengrui Pharmaceuticals Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.64 12.39 12.54 11.04 12.21

Jiangsu Hengrui Pharmaceuticals Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.43 11.60 15.29 12.21 10.85

MEX:1276N vs ZTS, UTHR: Cyclically Adjusted PB Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Jiangsu Hengrui Pharmaceuticals Co's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jiangsu Hengrui Pharmaceuticals Co Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Jiangsu Hengrui Pharmaceuticals Co's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Jiangsu Hengrui Pharmaceuticals Co's Cyclically Adjusted PB Ratio falls into.


MEX:1276N
60GF Score
Jiangsu Hengrui Pharmaceuticals Co Ltd MEX:1276N
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jiangsu Hengrui Pharmaceuticals Co Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Jiangsu Hengrui Pharmaceuticals Co's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 is calculated as:

For example, Jiangsu Hengrui Pharmaceuticals Co's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book=Book Value per Share/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=25.082/116.3033*116.3033
=25.082

Current CPI (Mar. 2026) = 116.3033.

Jiangsu Hengrui Pharmaceuticals Co Quarterly Data

Book Value per Share CPI Adj_Book
201606 4.908 101.400 5.629
201609 5.370 102.400 6.099
201612 5.833 102.600 6.612
201703 5.698 103.200 6.421
201706 5.732 103.100 6.466
201709 6.299 104.100 7.037
201712 7.234 104.500 8.051
201803 7.410 105.300 8.184
201806 8.154 104.900 9.040
201809 7.957 106.600 8.681
201812 8.901 106.500 9.720
201903 9.268 107.700 10.008
201906 9.518 107.700 10.278
201909 10.089 109.800 10.687
201912 10.461 111.200 10.941
202003 13.697 112.300 14.185
202006 13.588 110.400 14.315
202009 14.320 111.700 14.910
202012 14.503 111.500 15.128
202103 15.797 112.662 16.308
202106 15.878 111.769 16.522
202109 17.044 112.215 17.665
202112 17.626 113.108 18.124
202203 17.830 114.335 18.137
202206 16.990 114.558 17.249
202209 16.510 115.339 16.648
202212 16.581 115.116 16.752
202303 15.948 115.116 16.113
202306 14.584 114.558 14.806
202309 14.831 115.339 14.955
202312 15.080 114.781 15.280
202403 15.128 115.227 15.269
202406 16.873 114.781 17.097
202409 19.093 115.785 19.179
202412 20.441 114.893 20.692
202503 20.080 115.116 20.287
202506 23.099 114.907 23.380
202509 23.087 115.471 23.253
202512 23.600 115.832 23.696
202603 25.082 116.303 25.082

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Jiangsu Hengrui Pharmaceuticals Co (MEX:1276N) Overvalued in 2026?

Based on GuruFocus' analysis, Jiangsu Hengrui Pharmaceuticals Co stock appears to be undervalued. The current stock price of MXN125.92 is trading 11.9% below its estimated GF Value™ of MXN142.94. GuruFocus considers Jiangsu Hengrui Pharmaceuticals Co to be Modestly Undervalued.

Key valuation signals for MEX:1276N:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: MXN142.94 vs. price of MXN125.92 (11.9% below fair value)
  • GF Score™: 60/100 with 1 warning sign

No single metric tells the full story. See the MEX:1276N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Jiangsu Hengrui Pharmaceuticals Co Business Description

Address No. 7, Kunlunshan Road, Economic and Technological Development Zone, Jiangsu Province, Lianyugang, CHN, 222000
Jiangsu Hengrui Pharmaceuticals Co Ltd is a biopharmaceutical company that engages in the research, development, manufacture, and sale of drugs. It is engaged in the field of cancer treatment drugs, surgical medicines, endocrine therapy drugs, cardiovascular drugs, and anti-infection medications. The company specializes in the research and development of new medicines in areas of antineoplastics, endocrine system, cardiovascular, and the immune system. Geographically, the company is segmented as Chinese mainland and Other countries generating majority revenue from the Chinese region.
60GF Score

Get the complete analysis for MEX:1276N

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN125.92
Price
MXN142.94
GF Value